Table 6.
Risk of Hypertension in the entire participants according to plasma marker quartiles.
| Plasma Marker | Plasma markers | |||
|---|---|---|---|---|
| Quartile 1 | Quartile 2 | Quartile 3 | Quartile 4 | |
| hs-CRP | ≤0.50 | 0.51–1.01 | 1.02–1.94 | ≥1.95 |
| Model 1 | 1.000(ref.) | 1.35(1.08–1.67)‡ | 1.94(1.54–2.43)‡ | 1.83(1.46–2.30)‡ |
| Model 2 | 1.000(ref.) | 1.17(0.93–1.47) | 1.51(1.19–1.91)† | 1.30(1.02–1.66)* |
| Model 3 | 1.000(ref.) | 1.10(0.88–1.39) | 1.41(1.11–1.80)* | 1.17(0.91–1.51) |
| Hcy | ≤7.97 | 7.98–9.47 | 9.48–11.92 | ≥1.93 |
| Model 1 | 1.000(ref.) | 1.09(0.87–1.35) | 1.22(0.97–1.53) | 1.59(1.26–2.01)‡ |
| Model 2 | 1.000(ref.) | 1.06(0.84–1.33) | 1.17(0.92–1.47) | 1.52(1.19–1.94)‡ |
| Model 3 | 1.000(ref.) | 1.09(0.87–1.37) | 1.17(0.92–1.47) | 1.48(1.16–1.90)† |
| hs-TnT | ≤5.82 | 5.83–7.92 | 7.93–10.23 | ≥10.24 |
| Model 1 | 1.000(ref.) | 1.15(0.91–1.46) | 1.19(0.93–1.51) | 1.21(0.94–1.55) |
| Model 2 | 1.000(ref.) | 1.16(0.91–1.48) | 1.16(0.91–1.49) | 1.08(0.83–1.39) |
| Model 3 | 1.000(ref.) | 1.16(0.91–1.49) | 1.15(0.90–1.48) | 1.05(0.81–1.37) |
| NT-proBNP | ≤30.75 | 30.75–50.77 | 50.78–83.79 | ≥83.80 |
| Model 1 | 1.000(ref.) | 1.13(0.90–1.41) | 1.06(0.85–1.32) | 1.31(1.04–1.65)* |
| Model 2 | 1.000(ref.) | 1.25(0.99–1.57) | 1.18(0.93–1.49) | 1.53(1.21–1.95)* |
| Model 3 | 1.000(ref.) | 1.28(1.02–1.62) | 1.24(0.98–1.56) | 1.62(1.27–2.07)‡ |
| 25-OHD | ≤9.85 | 9.86–13.95 | 13.96–13.39 | ≥19.40 |
| Model 1 | 1.000(ref.) | 0.81(0.65–1.01) | 0.85(0.68–1.07) | 0.99(0.79–1.25) |
| Model 2 | 1.000(ref.) | 0.80(0.64–1.01) | 0.84(0.66–1.06) | 0.95(0.75–1.21) |
| Model 3 | 1.000(ref.) | 0.81(0.65–1.03) | 0.85(0.67–1.08) | 0.97(0.76–1.24) |
| HBA1C (%) | ≤4.72 | 4.73–5.09 | 5.10–5.66 | ≥5.67 |
| Model 1 | 1.000(ref.) | 1.08(0.87–1.34) | 1.21(0.97–1.51) | 2.31(1.84–2.90)‡ |
| Model 2 | 1.000(ref.) | 1.08(0.87–1.35) | 1.21(0.97–1.50) | 2.31(1.84–2.91)‡ |
| Model 3 | 1.000(ref.) | 1.06(0.85–1.33)‡ | 1.11(0.88–1.39) | 1.94(1.49–2.52)‡ |
| Model 4 | 1.000(ref.) | 1.06(0.85–1.34) | 1.10(0.88–1.39) | 1.96(1.51–2.56)‡ |
| SUA # | ||||
| Model 1 | 1.000(ref.) | 0.99(0.80–1.23) | 1.08(0.87–1.35) | 1.71(1.37–2.14) |
| Model 2 | 1.000(ref.) | 0.90(0.72–1.12) | 0.87(0.69–1.09) | 1.23(0.97–1.56) |
| Model 3 | 1.000(ref.) | 0.87(0.69–1.09) | 0.83(0.66–1.05) | 1.11(0.87–1.41) |
*P < 0.05; †P < 0.01; ‡P < 0.001.
#The cutoff points for the Serum Uric Acid were calculated for men and women separately, and the values are described in Tables 4 and 5.
hs-CRP = high-sensitivity C-reactive protein; hs-cTnT, high-sensitivity cardiac troponin T; NT-proBNP, N-terminal prohormone of brain natriuretic peptide; 25OHD, 25-Hydroxyvitamin D; SUA, serum uric acid and HbA1c, glycosylated hemoglobin A1c.
Model 1: Adjusted for age and gender.
Model 2: Adjusted for age, gender, smoking, Alcohol use, physical activity.
Model 3: Adjusted for the above plus total serum cholesterol, high-density lipoprotein, LDL-C, triglycerides and creatinine, BMI and Diabetes Mellitus.
Model 4: Sensitivity analysis for HBA1c markers.